CRISPR THERAPEUTICS AG (CRSP) Net income 2016–2025
CRISPR THERAPEUTICS AG (CRSP) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$581.6MFY2025 · since FY2016: -$23.2M → -$581.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$581.6M | -58.8% |
| FY2024 | -$366.3M | -138.4% |
| FY2023 | -$153.6M | +76.4% |
| FY2022 | -$650.2M | -272.2% |
| FY2021 | $377.7M | +208.3% |
| FY2020 | -$348.9M | -621.8% |
| FY2019 | $66.9M | +140.5% |
| FY2018 | -$165.0M | -141.4% |
| FY2017 | -$68.4M | -194.9% |
| FY2016 | -$23.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CRSP financial trends
CRSP RevenueCRSP Net marginCRSP Gross profitCRSP Gross marginCRSP Operating incomeCRSP Operating marginCRSP Operating cash flowCRSP Free cash flowCRSP Capital expendituresCRSP Return on equityCRSP Stock buybacksCRSP Dividends paidCRSP Total assetsCRSP Total liabilitiesCRSP Shareholders’ equityCRSP overview →